Montserrat García-Retortillo

Montserrat García-Retortillo

Auto-generated profile, based on publicly available information

Montserrat García-Retortillo

Digestive Diseases Department, Hospital del Mar-Parc de Salut Mar, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2002 in Hepatology
Verified
Journal Article
Open access
PDF file
MGMontserrat Garcia-Retortillo
Montserrat Garcia-Retortillo
XFXavier Forns
Xavier Forns
AFAnna Sant Feliu
Anna Sant Feliu
EMEduardo Moitinho
Eduardo Moitinho
JCJosep Costa
Josep Costa
JRJuan Rodes
Juan Rodes
The study of hepatitis C virus (HCV) kinetics after liver transplantation (LT) might be important to design strategies to prevent HCV infection of the graft. We analyzed HCV kinetics during and immediately after LT in 20 consecutive patients undergoing LT for HCV-related cirrhosis. HCV RNA was quantified in blood samples obtained at regular intervals before, during, and after transplantation. HCV-RNA concentrations decreased in 18 of 20 patients during the anhepatic phase (mean decay slope −0.92, mean HCV elimination half-life 2.2 hours). We found a significant correlation between the HCV viral load decay and the blood loss during the anhepatic phase, indicating that the observed HCV clearance rates are maximum estimates. In fact, in 1 patient with an unusually long anhepatic phase of 20 hours and with minimum blood loss, the HCV elimination half-life was 10.3 hours. Eight to 24 hours after graft reperfusion a sharp decrease in HCV viral load occurred in 19 patients (mean decay slope −0.34, mean HCV elimination half-life 3.44 hours). HCV RNA became undetectable in only 1 patient. During the following days, HCV-RNA concentrations increased rapidly in 10 patients (mean HCV doubling time 13.8 hours), remained at similar levels in 4, and continued to decrease in 6. The only variable associated with a second-phase viral load decay was the absence of corticosteroids as part of the immunosuppressive regimen. In conclusion, a sharp decrease in HCV viral load occurs during the anhepatic phase and immediately after graft reperfusion, most likely owing to a lack of virion production and hepatic viral clearance. HCV infection of the graft, however, is an extremely dynamic process and viral replication begins a few hours after LT. (Hepatology 2002;35:680-687.)

1 May 2007 in Gastroenterology
Verified
Journal Article
Open access
PDF file
JCJosé A. Carrión
José A. Carrión
MNMiquel Navasa
Miquel Navasa
MGMontserrat García–Retortillo
Montserrat García–Retortillo
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán
GCGonzalo Crespo
Gonzalo Crespo
XFXavier Forns
Xavier Forns
Background & Aims: Recurrence of hepatitis C virus (HCV) infection is a relevant problem of liver transplantation programs. We evaluated the effect of antiviral therapy on disease progression in 81 HCV-infected liver transplantation recipients. Methods: Patients with mild hepatitis C recurrence (fibrosis stage F0 to F2, n = 54) were randomized to no treatment (group A, n = 27) or peginterferon alfa-2b/ribavirin for 48 weeks (group B, n = 27). Patients with severe recurrence (F3 to F4, cholestatic hepatitis) were treated (group C, n = 27). All patients (n = 81) underwent a liver biopsy at baseline and after follow-up; paired hepatic venous pressure gradient (HVPG) measurements were available in 51 patients. Results: Thirteen (48%) patients of group B and 5 (18.5%) of group C achieved sustained virological response. Liver fibrosis progressed ≥1 stage in 40 (49%) of 81 patients: 19 (70%) of group A versus 7 (26%) of group B (P = .001) and in 14 (54%) of group C. HVPG increased (6.5 to 13 mm Hg, P < .01) in patients in whom fibrosis worsened, whereas it decreased (5 to 3.5 mm Hg, P = .017) or remained unchanged in those with fibrosis improvement or stabilization, respectively. The only variable independently associated with fibrosis improvement/stabilization was treatment (odds ratio [OR] =3.7, 95% confidence interval [CI] 1.3 to 10, P = .009). Among treated patients, alanine aminotransferase (ALT) normalization and viral clearance were independently associated with histological or hemodynamic improvement/stabilization (OR 5.3, 95% CI 1.5 to 18, P < .01; OR 7.4, 95% CI 1.4 to 38, P = .01; respectively). Conclusions: Our data demonstrate that in liver transplantation recipients, antiviral therapy slows disease progression (particularly in sustained virological responders), as shown by its effects on liver histology and on HVPG.

1 September 2003 in Journal of Hepatology
Verified
Journal Article
Closed access
XFXavier Forns
Xavier Forns
MGMontserrat Garcı́a-Retortillo
Montserrat Garcı́a-Retortillo
TSTrinidad Serrano
Trinidad Serrano
AFAnna Sant Feliu
Anna Sant Feliu
FSFrancisco Suarez
Francisco Suarez
JRJuan Rodés
Juan Rodés

30 August 2004 in Hepatology
Verified
Journal Article
Open access
PDF file
MGMontserrat Garcia-Retortillo
Montserrat Garcia-Retortillo
XFXavier Forns
Xavier Forns
JLJosep M. Llovet
Josep M. Llovet
MNMiquel Navasa
Miquel Navasa
AFAnna Sant Feliu
Anna Sant Feliu
ARAntoni Rimola
Antoni Rimola
Preliminary reports suggested that hepatitis C virus (HCV) infection has a more aggressive course following living donor liver transplantation (LDLT) compared to cadaveric liver transplantation (CLT). The aim of this prospective study was to establish if HCV disease recurrence differs between LDLT and CLT. A cohort of 116 consecutive HCV-infected patients undergoing 117 LTs in a single center from March 2000 to August 2003 were followed-up, including systematic liver biopsies. Severe recurrence (SR) was defined as biopsy-proven cirrhosis and/or the occurrence of clinical decompensation. After a median follow-up of 22 months (2.6-44 months), 26 (22%) patients developed SR (decompensation in 12), involving 17 (18%) of 95 patients undergoing CLT and 9 (41%) of 22 undergoing LDLT. The 2-year probability of presenting SR was significantly higher in LDLT compared to CLT (45% vs. 22%, P = .019). By univariate analysis LDLT (P = .019) and an ALT higher than 80 IU/L 3 months after LT (P = .022) were predictors of SR. In 93 patients from whom a liver biopsy was available 3 months after LT, a lobular necroinflammatory score >1 (P < .01), LDLT (P < .01), and biliary complications (P = .046) were associated with SR. However, the only variables independently associated with SR were LDLT (odds ratio [OR], = 2.8; 95% CI,1.19-6.6; P = .024) and a lobular necroinflammatory score >1 (OR, 3.1; 95% CI, 1.2-8; P = .013). In conclusion, HCV recurrence is more severe in LDLT compared to CLT. Although our results were based on a single-center experience, they should be considered in the decision-making process of transplant programs, since severe HCV recurrence may ultimately compromise graft and patient survival. (Hepatology 2004; 40:699-707.)

1 July 2010 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SMSilvia Montoliu
Silvia Montoliu
BBBelén Ballesté
Belén Ballesté
RPRamon Planas
Ramon Planas
MÁMarco Antonio Álvarez-González
Marco Antonio Álvarez-González
MRMònica Rivera
Mònica Rivera
RSRicard Solà
Ricard Solà

15 September 2004 in Transplantation
Verified
Journal Article
Closed access
ARAntoni Rimola
Antoni Rimola
MLMaría-Carlota Londoño
María-Carlota Londoño
GGGonzalo Guevara
Gonzalo Guevara
MBMiquel Bruguera
Miquel Bruguera
MNMiquel Navasa
Miquel Navasa
JRJuan Rodes
Juan Rodes
Hepatitis C recurrence after liver transplantation is often associated with accelerated graft fibrosis and progression to cirrhosis. Because drugs blocking the action of angiotensin-II can reduce fibrosis in different human and experimental models, we assessed the possible beneficial effect of these drugs on graft fibrosis in hepatitis C recurrence after liver transplantation. We retrospectively reviewed the charts of 128 liver-transplant recipients with hepatitis C recurrence. Twenty-seven patients (group I) received angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists as antihypertensive treatment, and 101 patients (group II) did not receive these drugs. No significant differences were found between groups I and II in demographic, clinical, and laboratory data. In contrast, cirrhosis in the graft was less frequently observed in group I than in group II during postransplant follow-up: 15% versus 35% (P=0.035), respectively, with a probability of cirrhosis of 9% versus 32% at 5 years after transplantation and 35% versus 70% at 10 years (P=0.0049). Furthermore, the fibrosis stage (scored from 0–4) in the liver biopsy obtained at the end of follow-up was significantly lower in group I than in group II (median [and range]: 1 [0–4] vs. 2 [0–4]; P=0.038), and the fibrosis progression index (increase of fibrosis stage per year) was also lower in group I than in group II (0.21 [0–0.45] vs. 0.52 [0–2.58]; P=0.006). The administration of angiotensin-blocking agents may be beneficial to reduce the development of graft fibrosis in hepatitis C recurrence after liver transplantation.